Biotech Values

[DewDiligence]

Here’s the Teva CC exchange vis-à-vis Lovenox:

Ken Cacciatore (Cowen) at 52:38: “…could you give us a regulatory update on Lovenox for both you and if you are aware of anything surrounding your competitor…”

Bill Marth (CEO, Teva North America) at 54:40: “...I wish I had a crystal ball and could tell you exactly when that approval will come… and I can’t really comment too much for the other players in the market. I’m not sure where Momenta is right now and I’m not real sure about Amphastar. What I do know is that we see the application progressing very nicely. We’re getting very normal questions back around labeling and all the typical stuff. So we do see activity and very positive activity.”